Signal-transducing mechanisms involved in activation of the platelet collagen receptor integrin alpha(2)beta(1).
Evidence was obtained about the mechanism responsible for platelet integrin alpha(2)beta activation by determining effects of various inhibitors on soluble collagen binding, a parameter to assess integrin alpha(2)beta(1) activation, in stimulated platelets. Agonists that can also activate platelet glycoprotein IIb/IIIa are able to activate integrin alpha(2)beta(1), but those operating via glycoprotein Ib cannot. Activation of alpha(2)beta(1) induced by low thrombin or collagen-related peptide concentrations was almost completely inhibited by apyrase, and the inhibitors wortmannin, 4-amino-5-(chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine, bisindolylmaleimide I, and SQ29548 significantly inhibited it. Activation induced by high thrombin or collagen-related peptide concentrations was far less sensitive to these inhibitors. However, only wortmannin markedly inhibited ADP-induced integrin alpha(2)beta(1) activation, and this was not ADP concentration-dependent. These results suggest that at the low agonist concentrations, the released ADP would be a primary inducer of integrin alpha(2)beta(1) activation, while at the high agonist concentrations, there would be several pathways through which integrin alpha(2)beta(1) activation can be induced. Kinetic analyses revealed that ADP-induced platelets had about the same number of binding sites (B(max)) as thrombin-induced platelets, but their affinity (K(d)) for soluble collagen was 3.7-12.7-fold lower, suggesting that activated integrin alpha(2)beta(1) induced by ADP is different from that induced by thrombin. The data are consistent with an activation mechanism involving released ADP and in which there exists two different states of activated integrin alpha(2)beta(1); these activated forms of integrin alpha(2)beta(1) would have different conformations that determine their ligand affinity.
Jung
S M
SM
Department of Protein Biochemistry, Institute of Life Science, Kurume University, 2432-3 Aikawa-machi, Kurume-shi, Fukuoka-ken, 839-0861, Japan. smj@mbox.lsi.kurume-u.ac.jp
Moroi
M
M
D000244:Adenosine Diphosphate / Q000494:pharmacology; D000730:Androstadienes / Q000494:pharmacology; D019086:Bridged Bicyclo Compounds, Heterocyclic; D003094:Collagen / Q000378:metabolism*; D005231:Fatty Acids, Unsaturated; D006834:Hydrazines / Q000494:pharmacology; D007211:Indoles / Q000494:pharmacology; D016023:Integrins / Q000819:agonists / Q000037:antagonists & inhibitors / Q000378:metabolism*; D007700:Kinetics; D008301:Maleimides / Q000494:pharmacology; D008954:Models, Biological; D010446:Peptide Fragments / Q000494:pharmacology; D010766:Phosphorylation / Q000187:drug effects; D010974:Platelet Aggregation / Q000502:physiology*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000378:metabolism; D011485:Protein Binding; D011487:Protein Conformation; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D038981:Receptors, Collagen; D015398:Signal Transduction; D013917:Thrombin / Q000494:pharmacology; D000077191:Wortmannin
D000730:Androstadienes; D019086:Bridged Bicyclo Compounds, Heterocyclic; D005231:Fatty Acids, Unsaturated; D006834:Hydrazines; D007211:Indoles; D016023:Integrins; D008301:Maleimides; D010446:Peptide Fragments; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D038981:Receptors, Collagen; D000244:Adenosine Diphosphate; C045749:SQ 29548; D003094:Collagen; D011505:Protein-Tyrosine Kinases; D013917:Thrombin; C070515:bisindolylmaleimide I; D000077191:Wortmannin